In:
International Journal of Cancer, Wiley, Vol. 144, No. 4 ( 2019-02-15), p. 859-867
Abstract:
What's new? Undifferentiated pleomorphic sarcomas (UPS), which are often associated with poor patient outcome, pose significant clinical challenges. An important reason for this is the absence of biomarkers capable of distinguishing patients at high risk of aggressive disease. Here, using bioinformatic and immunohistochemical analyses, the authors probed gene expression datasets for prognostic biomarkers in UPS patients. Patients with poor outcome were found to express intratumorally high levels of adenosine monophosphate deaminase 2 ( AMPD2 ), an enzyme involved in purine metabolism. Analyses revealed correlations between AMPD2 overexpression and copy number variations identified in UPS cohorts. AMPD2 overexpression was further associated with UPS tumor growth.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8